He joined Aix-Marseille University as a professor at the Centre d'Immunologie de Marseille-Luminy (CIML) in 1993 and became its director in 2008.
In 1999, Dr. Vivier cofounded the biotech company Innate-Pharma.
In 2014, he was one of the founders of the Marseille-Immunopole, an immunology cluster linking fundamental research, therapeutic innovation, and industrial development in the Aix-Marseille region.
The Vivier laboratory has since been a world leader in the generation of transgenic mouse models for the dissection of NK-cell function in vivo. Building on these basic research results, the Vivier laboratory has also been involved in the development of innovative treatments for cancer.
These studies on NK cells led to the involvement of the Vivier laboratory in the discovery of ILCs through the detection and characterization of the ILC3 cell subset in human and mouse intestine.